Parietaria judaica-specific T-cell receptor (Pj-TCR) (Pj-TCR)

The Parietaria judaica-specific T-cell receptor (TCR) is a specialized protein complex found on the surface of CD4+ T helper cells that recognizes allergenic peptides derived from Parietaria judaica pollen, such as Par j 1 and Par j 2, presented by Major Histocompatibility Complex (MHC) class II molecules [D'Amato et al., Allergy, 2007]. In sensitized individuals, the interaction between these allergens and the TCR triggers a Th2-polarized immune response, leading to the production of IgE antibodies and the release of inflammatory mediators responsible for allergic rhinitis and asthma [Cuesta-Herranz et al., JACI, 1998]. This receptor is a primary focus for allergen-specific immunotherapy (AIT), which aims to modify the T-cell response to induce long-term clinical tolerance. By targeting the TCR-mediated signaling pathway through controlled allergen exposure, clinicians can promote the development of regulatory T cells and reduce the allergic inflammatory cascade [Larche et al., Nature Reviews Immunology, 2006]. Understanding the specific TCR repertoire associated with Parietaria allergy is crucial for developing precision vaccines and monitoring the efficacy of desensitization treatments [Bonura et al., International Archives of Allergy and Immunology, 2012].

Other names

Parietaria judaica-specific T-cell receptors on CD4+ T cellsPellitory-of-the-wall specific T-cell receptorPar j 1-specific TCRPar j 2-specific TCRParietaria-specific CD4+ T-cell receptor

Allergen-specific immunotherapy (AIT) modulates the immune response by interacting with Parietaria judaica-specific T-cell receptors to induce peripheral T-cell tolerance. This is achieved through the induction of T-cell anergy, the deletion of allergen-specific Th2 cells, and the expansion of regulatory T cells (Tregs) that secrete inhibitory cytokines like IL-10 and TGF-beta [Akdis & Akdis, Nature Reviews Drug Discovery, 2014]. Over time, this leads to an immune deviation where the Th2-mediated allergic response is suppressed in favor of a Th1 or Treg-mediated response, reducing IgE production and allergic inflammation [Jutel et al., Allergy, 2011].